Compare RAYA & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RAYA | PMN |
|---|---|---|
| Founded | 2019 | 2004 |
| Country | China | Canada |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Pharmaceuticals and Biotechnology |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2M | 23.5M |
| IPO Year | 2022 | N/A |
| Metric | RAYA | PMN |
|---|---|---|
| Price | $4.16 | $7.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $72.67 |
| AVG Volume (30 Days) | 28.1K | ★ 31.5K |
| Earning Date | 04-17-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $27,101,325.00 | N/A |
| Revenue This Year | $20.95 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 18.78 | N/A |
| 52 Week Low | $3.13 | $6.27 |
| 52 Week High | $736.99 | $39.75 |
| Indicator | RAYA | PMN |
|---|---|---|
| Relative Strength Index (RSI) | 46.80 | 62.68 |
| Support Level | $4.20 | $8.00 |
| Resistance Level | $4.50 | $8.73 |
| Average True Range (ATR) | 0.47 | 0.57 |
| MACD | -0.04 | -0.33 |
| Stochastic Oscillator | 17.77 | 3.33 |
Erayak Power Solution Group Inc engages in manufacturing, research and development, and wholesale and retail of power solution products. Its product portfolio includes sine wave and off-grid inverters, inverter and gasoline generators, battery, and smart chargers, and custom-designed products. It derives the majority revenue from four products namely inverters, chargers, power bank, and gasoline generators. The company generates the majority of its revenue from Inverters. The company geographically operates in China, Australia, Poland, U.K., and Germany. It derives maximum revenue from China.
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.